Improve the Quality of Life of Women and Reduce Clinical and Morphological Features of Endometriosis under the Influence of Dienogest Preparation

Md. Babul Akter, Fatema Rahman, Abeda Muhammad Iqbal, Abul Basher Mohammed Iqbal
In: Journal of Comilla Medical College Teachers' Association · 2024 · vol. 28(2) , pp. 65–69 · doi:10.3329/jcomcta.v28i2.78014 · W4405402279
article OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

Dienogest treatment reduced abnormal uterine bleeding, pelvic pain, and endometrial glands in the myometrium, improving quality of life for women with endometriosis and adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text ⓘ

This randomized controlled study (January 2022–December 2023) evaluated how dienogest affected endometroid gland activity in the myometrium and related symptom severity and quality of life in women aged 20–50 diagnosed with adenomyosis based on pelvic pain, abnormal uterine bleeding, menstruation-related pain or heaviness, anemia, and transvaginal ultrasound. Participants were assigned to three 6-month regimens: dienogest 2 mg/day, Marvelon (estrogen/progesterone), or medroxyprogesterone acetate 10 mg continuously, with outcomes including bleeding and pain changes, hemoglobin, ultrasound findings, and a 25-item quality-of-life questionnaire. Dienogest was associated with complete cessation of genital tract bleeding in all 8 women reporting it, substantial pain improvement, decreased myometrial endometroid gland counts on transvaginal sonography, and quality-of-life improvement across parameters; similar symptom reductions were also reported in the comparator groups. The paper does not clearly state sample size per arm beyond 20 in groups 1 and 2/3, and some subgroup denominators for pain outcomes appear inconsistent, limiting interpretability. This paper centrally about endometriosis — with an emphasis on dienogest’s effects on endometroid glands and on reducing clinical features labeled for both endometriosis and adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: the aim of our study was to analyze the effect of dienogest on the endometroid glands in the myometrium. A transvaginal sonographic morphologic assessment of the effect of the drugs, taking into account its safety, as well as as an assessment of changes in the quality of life of women associated with decreases in the severity symptoms of adenomyosis and endometriosis. Objectives: To evaluate the effectiveness of Dienogest in improving quality of life to reduce clinical manifestation of adenomyosis. Methods: It is a randomized control study conducted from January 2022 to December 2023 that included women aged 20-50 years, which is diagnosed as adenomyosis by clinical presentation manifested by the presence of pelvic pain, abnormal uterine bleeding, painful, and or heavy menstruation, as well as the presence of anemia and transvaginal sonography. Patients were divided into 3 groups depending on the name of the drugs that they used. 20 patients of group 1 received the drug “dienogest” at 2 mg/day for 6 months. The second group received the combined oral contraceptive drug, “Marvelon “which contains estrogen and progesterone. The third group included 20 patients who received only progesterone “medroxy”10 mg continuously for 6 months. Result: After the starting of drugs for 6-12 months bloody discharge from the genital tract in group 1 completely stopped in all 8 women. In group ii, the discharge decreased in 3 women and completely stopped in 6 women. In group iii, the discharge decreased in 3 women and completely stopped in 5 women. pain in group 1 completely stopped in 5 women out of 6(83.3%) and 2 women decreased pain out of 6 (33.4%) in the second group the pain stopped completely in 6 women out of 10 (58.3%) and decreased in 4 women out of 10 (34.66%). In the third group, pain completely recovered in 6 out of 10 (60%) and decreased in 4 women out of 10 (40%). According to transvaginal sonographic evidence of myometrium with endometroid glands before treatment, group 1 had 12.2± 3.8 glands before treatment and 1.4 ± .8 after treatment. In the second group, the number of glands before treatment was 10.8 ±1.4 and after treatment 3.8 ±.7 glands. in the third group before treatment, 6.7 ± 2.1 endometroid glands were determined and after treatment 2.7 ±1.4 glands in the field of view. Conclusion: Dienogest is effective in the treatment of endometriosis and reduces both the clinical manifestations of adenomyosis (abnormal uterine bleeding and chronic pelvic pain) and increases hemoglobin levels, together with a decrease in the activity of the endometroid glands in the myometrium. Dienogest is highly selective progesterone against progesterone receptors and has anti-proliferative activity in isolated human endometrial cells. Given the indicators of the 25-item short-form survey questionnaire, the quality of life in all the studied groups improved in all parameters, which indicates the effectiveness of the dienogest-containing drugs used. J Com Med Col Teachers Asso July 2024; 28(2): 65-69
Full text 3,598 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Background

the aim of our study was to analyze the effect of dienogest on the endometroid glands in the myometrium. A transvaginal sonographic morphologic assessment of the effect of the drugs, taking into account its safety, as well as as an assessment of changes in the quality of life of women associated with decreases in the severity symptoms of adenomyosis and endometriosis.

Objectives

To evaluate the effectiveness of Dienogest in improving quality of life to reduce clinical manifestation of adenomyosis.

Methods

It is a randomized control study conducted from January 2022 to December 2023 that included women aged 20-50 years, which is diagnosed as adenomyosis by clinical presentation manifested by the presence of pelvic pain, abnormal uterine bleeding, painful, and or heavy menstruation, as well as the presence of anemia and transvaginal sonography. Patients were divided into 3 groups depending on the name of the drugs that they used. 20 patients of group 1 received the drug “dienogest” at 2 mg/day for 6 months. The second group received the combined oral contraceptive drug, “Marvelon “which contains estrogen and progesterone. The third group included 20 patients who received only progesterone “medroxy”10 mg continuously for 6 months.

Result

After the starting of drugs for 6-12 months bloody discharge from the genital tract in group 1 completely stopped in all 8 women. In group ii, the discharge decreased in 3 women and completely stopped in 6 women. In group iii, the discharge decreased in 3 women and completely stopped in 5 women. pain in group 1 completely stopped in 5 women out of 6(83.3%) and 2 women decreased pain out of 6 (33.4%) in the second group the pain stopped completely in 6 women out of 10 (58.3%) and decreased in 4 women out of 10 (34.66%). In the third group, pain completely recovered in 6 out of 10 (60%) and decreased in 4 women out of 10 (40%). According to transvaginal sonographic evidence of myometrium with endometroid glands before treatment, group 1 had 12.2± 3.8 glands before treatment and 1.4 ± .8 after treatment. In the second group, the number of glands before treatment was 10.8 ±1.4 and after treatment 3.8 ±.7 glands. in the third group before treatment, 6.7 ± 2.1 endometroid glands were determined and after treatment 2.7 ±1.4 glands in the field of view.

Conclusion

Dienogest is effective in the treatment of endometriosis and reduces both the clinical manifestations of adenomyosis (abnormal uterine bleeding and chronic pelvic pain) and increases hemoglobin levels, together with a decrease in the activity of the endometroid glands in the myometrium. Dienogest is highly selective progesterone against progesterone receptors and has anti-proliferative activity in isolated human endometrial cells. Given the indicators of the 25-item short-form survey questionnaire, the quality of life in all the studied groups improved in all parameters, which indicates the effectiveness of the dienogest-containing drugs used. J Com Med Col Teachers Asso July 2024; 28(2): 65-69 234 246 Downloads Published How to Cite Issue Section License Copyright (c) 2024 Journal of Comilla Medical College Teachers' Association This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisadenomyosischronic_pelvic_pain

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (2)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK